Rezolute to Participate in Upcoming Investor Conferences
Rezolute, Inc. (Nasdaq: RZLT), a late-stage rare disease company focusing on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI), has announced its participation in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rezolute, Inc. (Nasdaq: RZLT), a late-stage rare disease company focusing on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI), has announced its participation in two upcoming investor conferences. The company will attend the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, and the Cantor Global Healthcare Conference from September 17-19, 2024.
During these events, Rezolute's management team will be available for one-on-one meetings with investors. Interested parties are encouraged to contact their H.C. Wainwright and Cantor representatives to schedule meetings. This participation provides an opportunity for investors to gain insights into Rezolute's progress in addressing rare diseases, particularly its work on hypoglycemia caused by hyperinsulinism.
Details
News Market Reaction – RZLT
The recorded move for RZLT in the trading session of this news was +1.91%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI), today announced that management will participate in the following investor conferences:
Event: H.C. Wainwright 26th Annual Global Investment Conference
Date: September 9-11, 2024
Event: Cantor Global Healthcare Conference
Date: September 17-19, 2024
Management will be participating in one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their H.C. Wainwright and Cantor representatives.
About Rezolute, Inc.
Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, RZ358 (ersodetug), is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital hyperinsulinism (cHI) and tumor hyperinsulinism (tHI).
Contacts:
Rezolute, Inc.
Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717
LHA Investor Relations
Tirth T. Patel
tpatel@lhai.com
212-201-6614
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.